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SUMMARY 
Despite advances in cancer treatments, cancer is still ranked the second leading cause of 
death. Cancers are started by cancer stem cells (CSCs). CSCs, also called tumor-initiating cells, 
are found in tumors and are responsible for the growth of tumors and the spread of cancer to 
other parts of the body. CSCs are very resistant, and cannot be killed by chemotherapy or 
radiation treatments. These cells can come from healthy stem cells. The environment 
surrounding the healthy stem cells and mature cells can cause mutations in the cell’s genetics, 
resulting in development of CSCs. The environment can also increase tumor resistance to drugs. 
During preliminary experiments in our laboratory, we have found how the culture environment 
leads to mutation of human brain cancer cells. The cancer cells were also found to be drug-
resistant and have the ability to change shape to resemble colonies of other stem cells.  
In this project, we hypothesized that stressful conditions cause normal cells to change 
into CSCs capable of travelling throughout the body. To test the hypothesis, we attempted to 
examine which environmental changes cause conversion of cancer cells to CSCs. A U87 cell line 
was cultured in a MEM-FBS solution and concentrations of the antibiotic G418 were 
administered. The response of the cells to the G418 dosages was quantified by recording the cell 
confluency over several days. Changes in cell morphology were also recorded.  
This work did not result in any CSC-like cells. Cells not treated with G418 proliferated to 
100% confluency, but all dosages of G418 resulted in at most 8% cell confluency. Cell clusters 
formed in some of the wells of the cell plates. Future work should use different antibiotic 
concentrations to find where the cell confluency eventually remains constant. 
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INTRODUCTION 
Background 
Cancer is still the second leading cause of death, despite advances in surgery, 
radiotherapy, and chemotherapy for cancer treatment. According to the American Cancer 
Society, there are an estimated 13.7 million cancer survivors alive in the US, and that number 
will increase to almost 18 million by 2022 (1). Based on the results from recent studies, the cure 
for cancer requires eliminating the subset of cells that support tumor growth, which is believed to 
be cancer stem cells (CSCs) (10). Therefore, there is an urgent need to understand the process of 
how normal and healthy cells develop into CSCs, and why advanced tumor cells are likely to 
invade other organs. 
CSCs are cancer cells found within tumors, and they retain characteristics associated with 
the normal stem cells. Even though chemotherapy and radiation can suppress or shrink cancer 
tumors, they do not kill CSCs, as CSCs are resistant to many anticancer agents and known to be 
strongly radiation resistant (2). CSCs are predicted to be responsible for tumor initiation and 
maintenance. CSCs not only support the growth and transmission of tumors, but also replenish 
the other cell types that constitute the tumor (13). CSCs do not necessarily act under the same 
internal and external factors as non-cancerous stem cells (13). They also drive metastasis, which 
is the major cause of death in advanced cancer (2-3). In addition, as tumor growth advances, 
there is a higher chance that new CSCs will be produced by the tumor (10). These new CSCs can 
continuously divide, unlike the differentiated cells that are also produced by the tumor (10). 
Chemotherapeutics are likely to only target the bulk cells that do not continuously divide which 
results in a relapse of tumor formation (13). Some researchers suggest a cancer therapy treatment 
that influences CSCs to produce non-dividing cells, instead of killing off the CSCs (10). 
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However, some researchers believe that all tumor cells, not just CSCs, can renew and continue 
tumor growth (13).  
CSCs can be formed in many ways, and are derived from sources other than genetic 
mutations of non-cancerous stem cells (14). Adult stem cells can spontaneously change into 
CSCs, or a differentiated cell can dedifferentiate back into a stem cell by obtaining stem cell 
characteristics through mutation (12). As shown in Fig. 1., the initial CSC niche consists of a few  
 
 
differentiating CSCs (14). As the tumor continues to develop, the placement of blood vessels 
(red), differentiated cells (blue), and non-differentiated cells (yellow) continues to change. 
Recent studies suggest that environments surrounding cells and tissues have great impact on cell 
mutation and tumorigenesis. For instance, hypoxic (low oxygen tension) environment may 
induce mouse neural and human mesenchymal stem cells to undergo genomic variability, and the 
genomic alteration leads to the foundation of a subpopulation of CSCs (4). Additional evidence 
of tumorigenesis is that increased expression of CSC markers, including CD133 and HIF2α, in a 
normal stem cell population can be detected after low oxygen tension treatment (6-7). CD133 is 
a marker of human brain tumors, and its expression is used to purify glioma-initiating CSCs by 
Figure 1. The CSC niche changes as the tumor grows (14). 
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fluorescence (17). Also, grade 3 gliomas have an abundance of CSCs according to their stemness 
signatures (17). 
 In addition, an acidic environment increases the resistance of glioma cells to multiple 
drugs, the expression of CSC markers, and tumor formation (8). Very recently, a process called 
epithelial-mesenchymal transition (EMT) was discovered. EMT does not occur in normal adult 
cells because it is silenced, but the inducers of EMT in cancer cells are overexpressed (16). The 
plasticity of CSCs allow this process to occur and it is when epithelial cells lose their defining 
characteristics and obtain mesenchymal properties, and it may imply the formation of another 
metastatic tumor (16). These cells show increased invasiveness and resistance to programmed 
cell death. The EMT process allows cells to migrate through blood and lymphatic vessels to 
invade different organs (9). Because tumors can become vascular and can affect the rate of 
angiogenesis, angiogenesis is a major exit route from the initial tumor site into blood circulation 
(11). Therefore, EMT can be a critical route of tumor metastasis and an origin of carcinoma 
subpopulations.   
 
Rational 
As mentioned above, CSCs are tumor-initiating cells. They are deliberated to originate 
from a mutation in normal stem cells. In our preliminary experiments, we found that a population 
of drug-resistant human brain cancer cells can be readily formed under certain culture conditions. 
These cancer cells not only demonstrated resistance to antibiotics, but also modified their shape 
by forming colonies similar to human pluripotent stem cells. Thus, it was hypothesized that 
stress induces the formation of carcinoma cells from normal cells, and that somatic cells under 
stressful condition can be genetically mutated into CSCs that possess high migration capability. 
Shields 5
The microenvironmental cues that stimulate the conversion of cancer cells into CSCs, which is 
the beginning of malignant tumor-initiating cells, were investigated using the following methods.  
 
Significance 
The results of this proposed work were intended to provide knowledge on malignant 
tumor formation as a subpopulation inside a tumor at its early stage; a CSC line established in 
this study was used as an in vitro model for drug discovery that is specifically targeting CSCs. 
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MATERIALS AND METHODS 
Research and lab work took place at Dr. Sha Jin’s lab at the University of Arkansas 
Engineering Research Center. Time was spent reading up on current research related to the 
project. In addition, time was spent in the lab to learn basic lab procedures, including culturing 
cells, immunostaining (Appendix B), and DNA transfection (Appendix C).  
Culture medium for the U-87 MG cells (Appendix A) was prepared by combining 117 ml 
of MEM and 13 ml of FBS in a 125 ml bottle, and was kept refrigerated at -20°C. U-87 MG cells 
were obtained from a liquid nitrogen freezer in the lab, and warmed in a 37°C water bath. The 
medium was also warmed in a 37°C water bath. The cells were transferred to a 15 ml tube, and 
4.5 ml of medium was added. The cells were centrifuged for 5 min at 1.3 rpm. After 
centrifuging, the supernatant was removed from the tube, and 2 ml of medium was added. The 
cells and medium were pipetted several times to mix. The cells were transferred to a 75 cm2 
flask, and 11 ml of medium was added. The flask was stored in a CO2 incubator for two days.  
After two days, the cells were viewed under a microscope and the cells appeared to be 
attached to the bottom of the flask. The medium was aspirated, and the cells were rinsed with 3 
ml of DMEM. Next, 2 ml of Trypsin-EDTA was added to the cells, and the flask was returned to 
the incubator for 3 min. The flask was removed, and 4 ml of medium was added to the flask, and 
the contents were transferred to a 15 ml tube. The cells were centrifuged for 5 min at 1.3 rpm, 
then the supernatant was aspirated, and 7 ml of medium was added. The medium and cells were 
mixed by pipetting several times. Next, 1 ml of cells was transferred to a clean 75 cm2 flask, and 
11 ml of medium was added to the flask. The flask was returned to the incubator. The medium 
was removed from the flask every two days, and 12 ml of fresh medium was added.  
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To plate the remaining cells in the tube, 6 ml of medium was added to the cells and 
mixed, then 1 ml of cells were transferred to each well in a 12-well plate. Next, the antibiotic 
G418 (50 mg/ml) was added to the cells. The table below shows the volume of dose added to 
each well, and the concentration of G418 in each well. No antibiotic was added to 4C as a 
control.  
 1 2 3 4 
A 5 µl 
0.25 mg/ml 
5 µl 
0.25 mg/ml 
10 µl 
0.5 mg/ml 
10 µl 
0.5 mg/ml 
B 15 µl 
0.75 mg/ml 
15 µl 
0.75 mg/ml 
20 µl 
1.0 mg/ml 
20 µl 
1.0 mg/ml 
C 25 µl 
1.25 mg/ml 
25 µl 
1.25 mg/ml 
30 µl 
1.5 mg/ml 
0 µl 
0 mg/ml 
  
 
 
The cells were observed daily for 26 days using a microscope, and the cell confluency 
was measured daily and recorded. Every other day, the medium was removed from each well, 
and 1 ml of fresh medium was added to each well, along with a dose of G418 following Table 1.  
After 5 days, more cells were plated from the 75 cm2 flask. The medium was warmed in a 
water bath, and the flask was removed from the incubator. The medium was aspirated, and the 
cells were rinsed with 3 ml of DPBS, then 2 ml of Trypsin-EDTA was added. The flask was 
placed back in the incubator, and after 3 min it was removed and 4 ml of medium was added. 
The cells were transferred to a 15 ml tube and centrifuged for 5 min at 1.3 rpm. The tube was 
removed from the centrifuge and the supernatant was aspirated, then 7 ml of medium was added 
to the tube. The cells were plated in a 6-well plate by removing 3 ml of the cells and distributing 
0.5 ml of those cells to each well in the 6-well plate. Next, 1.5 ml of medium was added to each 
Table 1. G418 Doses.  
This table shows the volume of G418 added to each well 
and the concentration of G418 in each well.  
 
Shields 8
well. Next, the antibiotic G418 (50 mg/ml) was added to the cells. The table below shows the 
volume of dose added to each well, and the concentration of G418 in each well. No antibiotic 
was added to A3 and B3 as a control.  
 
 1 2 3 
A 5 µl 
0.125 mg/ml 
10 µl 
0.25 mg/ml 
0 µl 
0 mg/ml 
B 5 µl 
0.125 mg/ml 
10 µl 
0.25 mg/ml 
0 µl 
0 mg/ml 
  
 
 
The cells were observed daily for 21 days using a microscope, and the cell confluency 
was measured daily and recorded. Every other day, the medium was removed from each well, 
and 1 ml of fresh medium was added to each well, along with a dose of G418 following Table 2. 
Finally, for both plates, the average percent cell confluency was calculated for the 
different dosages. Scatter plots of the averages were created to observe the changes in percent 
cell confluency.  
 
 
 
 
 
 
 
Table 2. G418 Doses.  
This table shows the volume of G418 added 
to each well and the concentration of G418 
in each well.  
 
Shields 9
RESULTS 
Only the cells that received no G418 (control) continued to grow and fill the well to 
100% confluency. Initially, some of the control cells died, but they quickly recovered and 
continued to grow and formed tumor spheroids until the plate was full to 100% confluency. The 
tumor spheroids looked very similar to the one depicted in Fig. 2.  
 
 
 
 
 The tables of percent cell confluency are in the appendix. The table of confluencies for 
the 12-well plate is in Appendix D, and the table for the 6-well plate is in Appendix E. Below is 
the graph (Fig. 3) of percent cell confluencies observed for the 12-well plate. From the graph, 
cells appeared to die faster initially with increased G418 concentration. However, after about 
Day 7, the cell confluency appeared to decline at about the same rate until Day 26.  
 
Figure 2.Tumor Spheroid (15). 
The control cells that received no antibiotic grew until they 
reached 100% cell confluency. Tumor spheroids formed in 
the wells that looked similar to this one.  
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 Overtime, the cells that received 5-20 µl of G418 in the 12-well plate stayed small and 
round, and formed small clusters. The cells that received 25-30 µl of G418 stayed small and 
round, and did not form clusters.    
Below is the graph (Fig. 4) of percent cell confluencies observed for the 6-well plate. The 
results from the 6-well plate were similar to the results of the 12-well plate. Only the cells 
receiving no G418 survived, and the cells in the remaining wells appeared to decline at about the 
same rate. However, there was not a sharp decline until Day 9, compared to Day 7 for the 12-
well plate. The cells that received 5 µl of G418 in the 6-well plate had a morphology that 
resembled glial cells, and several clusters formed. The cells receiving 10 µl of G418 were more 
round and few looked similar to glial cells. Also, fewer clusters of cells formed.  
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Figure 3. Percent Cell Confluency.  
Most of the cells died, except for those in the control that were administered no antibiotic.  
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Most of the cells died, except for those in the control that were administered no 
antibiotic.  
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DISCUSSION 
Different doses of the antibiotic G418 were administered to U87-MG cells at an attempt 
to observe the transformation of the cells to CSC-like cells. CSC-like cells were not observed, 
since all of the cells that received G418 continued to die until they reached low percent cell 
confluencies. For CSC-like cells, the percent cell confluency would have stayed constant after an 
initial decrease. The 6-well plate was an attempt to dilute the G418 in attempt to find a 
concentration where the cells would overcome the antibiotic and stay at a constant percent 
confluency. Possible errors were made in estimating percent confluency, since it was measured 
by eye, and dead cells may have been confused with live cells.  
Future work should test different G418 concentrations, or different antibiotics to find 
which antibiotic and concentration will cause the cells to resemble CSCs. Also, any cell clusters 
formed should be analyzed. Future work could increase knowledge on how malignant tumors 
grow and spread, and potentially lead to new cancer treatment strategies. 
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• ATCC" Product Information Sheet for ATCC® HTB-14™ 
Cell Line Designation: U-87 MG 
ATCC Catalog No. HTB-14™ 
Table of Contents: 
• Cell Line Description 
• Biosafety Level 
• Use Restrictions 
• Handling Procedure for Frozen Cells 
• Handling Procedure for Flask Cultures 
• Subculturing Procedure 
• Medium Renewal 
• Complete Growth Medium 
• Cryoprotectant Medium 
• References 
Cell Line Description 
Organism: Homo sapiens (human) 
Tissue: brain; glioblastoma; astrocytoma 
Age: 44 years 
Tumor Stage: classified as grade IV as of 2007 
Gender: male 
Ethnicity: caucasian 
Morphology: epithelial 
Growth properties: adherent 
Tumorigenic: yes, Tumors developed within 21 days at 100% 
frequency (5/5) in nude mice inoculated subcutaneously with 
10(7) cells 
AntigenExp: Blood Type A, Rh+ 
DNA profile (STR analysis): 
D5S818: 11,12 
D13S317: 8,11 
D7S820: 8,9 
D16S539: 12 
vWA: 15,17 
TH01: 9.3 
TPOX: 8 
CSF1PO: 10,11 
Amelogenin: X 
Depositors: J. Ponten 
Comments: This is one of a number of cell lines derived from 
malignant gliomas (see also ATCC HTB-15™ and ATCC HTB-
16TM) by J. Ponten and associates from 1966 to 1969. 
Mycoplasma contamination was eliminated in September 
1975. 
Note: ATCC has confirmed that the ATCC® HTB-14™ cell line 
is male in origin based on STR, Y-chromosome paint and Q-
band assays. However, based on the current literature, the 
cell line is still of glioblastoma origin and the discrepancy of 
gender is not unusual. It is possible that the cell line was 
misidentified in the depositor's original publication. 
Karyology: This is a hypodiploid human cell line with the 
modal chromosome number of 44 occurring in 48% of cells. 
The rate of higher ploidy was 5.9%. Twelve markers were 
ATCC® (American Type Culture Collection) 
P.O. Box 1549 
Manassas, VA 20108 USA 
www.atcc.org 
- 1 -
common to all cells, including der(1)t(1;3) (p22;q21), 
der(16)t(1;16) (p22;p12), del(9) (p13) and nine others. The 
marker der(1) had two copies in most cells. There was only 
one copy of normal X. N1, N6 and N9 were not found. 
Note: Cytogenetic information is based on initial seed stock at 
ATCC. Cytogenetic instability has been reported in the 
literature for some cell lines. 
Biosafety Level: 1 
Appropriate safety procedures should always be used with this 
material. Laboratory safety is discussed in the following 
publication: Biosafety in Microbiological and Biomedical 
Laboratories, 4th ed. HHS Publication No. (CDC) 93-8395. 
U.S. Department of Health and Human Services, Centers for 
Disease Control and Prevention. Washington DC: U.S. 
Government Printing Office; 1999. The entire text is available 
online at www.cdc.gov/od/ohs/biosfty/bmbl4/bmb14toc.htm 
Use Restrictions 
These cells are distributed for research purposes only. 
ATCC recommends that individuals contemplating commercial 
use of any cell line first contact the originating investigator to 
negotiate an agreement. Third party distribution of this cell line 
is discouraged, since this practice has resulted in the 
unintentional spreading of cell lines contaminated with 
inappropriate animal cells or microbes. 
Handling Procedure for Frozen Cells 
To insure the highest level of viability, thaw the vial and initiate 
the culture as soon as possible upon receipt. If upon arrival, 
continued stcrage of the frozen culture ..i.~tnecessary, _it should 
be stored in liquid nitrogen vapor phase and not at -70°C. 
Storage at -70°C will result in loss of viability. 
SAFETY PRECAUTION: ATCC highly recommends that 
protective gloves and clothing always be used and a full 
face mask always be worn when handling frozen vials. It 
is important to note that some vials leak when submersed in 
liquid nitrogen and will slowly fill with liquid nitrogen. Upon 
thawing, the conversion of the liquid nitrogen back to its gas 
phase may result in the vessel exploding or blowing off its cap 
with dangerous force creating flying debris. 
1. Thaw the vial by gentle agitation in a 37"C water bath. To 
reduce the possibility of contamination, keep the 0-ring 
and cap out of the water. Thawing should be rapid 
(approximately 2 minutes). 
Z. Remove the vial from the water bath as soon as the 
contents are thawed, and decontaminate by dipping in or 
spraying with 70% ethanol. All of the operations from this 
point on should be carried out under strict aseptic 
conditions. 
3. Transfer the vial contents to a centrifuge tube containing 
9.0 ml complete culture medium. and spin at 
approximately 125 xg for 5 to? minutes. 
800-638-6597 or 703-365-2700 
Fax: 703-365-2750 
E-mail: tech@atcc.org 
Or contact your local distributor. 
-------- - ~- ---
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• ATCC" Product Information Sheet for A TCC® HTB-14™ 
4. Resuspend cell pellet with the recommended complete 
medium (see the specific batch information for the culture 
recommended dilution ratio). and dispense into a 25 cm2 
or a 75 cm2 culture flask. It is important to avoid excessive 
alkalinity of the medium during recovery of the cells. It is 
suggested that, prior to the addition of the vial contents, 
the culture vessel containing the complete growth medium 
be placed into the incubator for -at least 15 minutes to 
allow the medium to reach its normal pH (7.0 to 7.6). 
5. Incubate the culture at 37"C in a suitable incubator. A 5% 
C02 in air atmosphere is recommended if using the 
medium described on this product sheet. 
Handling Procedure for Flask Cultures 
The flask was seeded with cells (see specific batch 
information) grown and completely filled with medium at ATCC 
to prevent loss of cells during shipping. 
1. Upon receipt visually examine the culture for macroscopic 
evidence of any microbial contamination. Using an 
inverted microscope (preferably equipped with phase-
contrast optics), carefully check for any evidence of 
microbial contamination. Also check to determine if the 
majority of cells are still attached to the bottom of the flask; 
during shipping the cultures are sometimes handled 
roughly and many of the cells often detach and become 
suspended in the culture medium (but are still viable). 
2. If the cells are still attached, aseptically remove all but 5 
to 10 ml of the shipping medium. The shipping medium 
U:tll be saved for reuse. lncutlatellle cells at-37\; ma 
5% C02 in air atmosphere until they are ready to be 
subcultured. 
3. If the cells are not attached, aseptically remove the 
entire contents of the flask and centrifuge at 125 xg for 5 
to 10 minutes. Remove shipping medium and save. 
Resuspend the pelleted cells in 10 ml of this medium and 
add to 25 cm2 flask. Incubate at 37"C in a 5% C02 in air 
atmosphere until cells are ready to be subcultured. 
Subculturing Procedure 
Volumes used in this protocol are for 75 cm2 flask; 
proportionally reduce or increase amount of dissociation 
mP.dium for culture vessels of other sizes. 
1. Remove and discard culture medium. 
2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin-
0.53mM EDTA solution to remove all traces of serum 
which contains trypsin inhibitor. 
3. Add 2.0 to 3.0 ml ofTrypsin-EDTA solution to flask and 
observe cells under an inverted microscope until cell layer 
is dispersed (usually within 5 to 15 minutes). 
Note: To avoid clumping do not agitate the cells by hitting 
or shaking the flask while waiting for the cells to detach. Cells 
ATCC® (American Type Culture Collection) 
P.O. Box 1549 
Manassas, VA 20108 USA 
www.atcc.org 
that are difficult to detach may be placed at 37°C C to facilitate 
dispersal. 
4. Add 6.0 to 8.0 ml of complete growth medium and aspirate 
cells by gently pipetting. 
5. Add appropriate aliquots of the cell suspension into new 
culture vessels. 
Subcultivation Ratio: 1 :2 to 1:5 
6. Incubate cultures at 3rC. 
Note: For more information on enzymatic dissociation and 
subculturing of cell lines consult Chapter 10 in Culture of 
Animal Cells, a manual of Basic Technique by R. ian 
Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994. 
Medium Renewal tc-1 ' · · , 
2 to 3 times weekly. C u)-hJid 'Z I C: 1 •:::· 
Complete Growth Medium frepo.r~-f//3d• .. JJt · 
The base medium for this cell line is ATCC-formulated Eagle's 
Minimum Essential Medium, Catalog No. 30-2003. 
To make the complete growth medium, add the following 
components to the base medium: 
• fetal bovine serum to a final concentration of 10% 
This medium is formulated for use with a 5% C02 in air 
atmosphere. 
ATCC tested fetal bovine serum is available as ATCC Catalog 
. l'W .. 30-2020 - ----------· 
- 2. 
Cryoprotectant Medium 
Complete growth medium described above supplemented with 
5% (v/v) DMSO. Cell culture tested DMSO is available as 
ATCC Catalog No. 4-X. 
Additional Information 
Additional product and technical information can be obtained 
from the catalog references and the ATCC Web site at 
www.atcc.org, or by e-mail at tech@atcc.org. 
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Cell Signaling 
Immunofluorescence General Protocol 
IMPORTANT: Please refer to the APPLICATIONS section on the front page of the datasheet to determine if this 
product is validated and approved for use on cultured cell lines (IF-IC), paraffin-embedded samples (IF-P), or frozen 
tissue sections (IF-F). Please see product datasheet for appropriate antibody dilution and unmasking solution. 
A. Solutions and Reagents 
NOTE: Prepare solutions with Milli-Q or equivalently purified water. 
1. 10X Phosphate Buffered Saline (PBS): To prepare 1L add' 80 g sodium chloride (NaCI), 2 g potassium 
chloride (KCI), 14.4 g sodium phosphate, dibasic (Na2HP04) and 2.4 g potassium phosphate, monobasic 
(KH2P04) to 1 L dH20. ~djust pH to 8.0. 
2. Formaldehyde, ~~~~ethanol free, Polysciences, Inc. (cat# 18814), use fresh, store opened \1als at 4°C in 
dark, dilute in PBS for use. 
3. Blocking Buffer: (1X PBS I 5% normal goat serum (#5425) I 0.3% Triton X-100): 
To prepare.l,(lddllfm110XPBS,.,I normal serum from the same species as the secondary 
antibody (e.g., n~rmal goat serum, normal donkey serum) an~ml dH20 and mix well. While stirring, add 
X-100. 
4. Dilution Buffer (1X PBS I 1% BSA I 0.3% Triton X-100): 
To prepare Jfnl. to,., Bring to final \Qiume of 40 ml with 
and m1x well. 
5. Fluorochrome-conjugated secondary antibody (recommended secondary antibodies) 
NOTE: When using any primary or fluorochrome-conjugated secondary antibody for the first time, titrate the 
antibody to determine which dilution allows for the strongest specific signal with the least background for your 
sample. 
6. Prolong® Gold Antifade Reagent (ln\1trogen, Eugene, OR, cat# P36930) 
Reagents specific to IF-P application: 
1. Xylene 
2. Ethanol, anhydrous denatured, histological grade, 100% and 95%. 
3. Antigen Unmasking: 
a. For Citrate: 10 mM Sodium Citrate Buffer: To prepare 1L add 2.94 g sodium citrate trisodium salt 
dihydrate (C6H5Na307•2H20) to 1 L dH20. Adjust pH to 6.0. 
b. For EDTA: 1 mM EDTA: To prepare 1L add 0.372 g EDTA (C1oH14N20aNa2•2H20) to 1L dH20. 
Adjust pH to 8.0 . 
.J3. Specimen Preparation 
I. Cultured Cell Lines (IF-IC) 
NOTE: Cells should be grown, treated, fixed and stained directly in multi-well plates, chamber slides or on coverslips. 
1. Aspirate liquid, then cover cells to a depth of 2-3 mm with 4% formaldehyde in PBS. 
NOTE: Formaldehyde is toxic, use only in fume hood. 
2. Allow cells to fix for 15 minutes at room temperature. 
3. Aspirate fixative, rinse three times in PBS for 5 minutes each. 
4. Proceed with lmmunostaining (Section C). 
www.cellsignal.com/support/protocols!IF.html 
~~- ------- ~---
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II. Paraffin Sections (IF-P) 
NOTE: Do not allow slides to dry at any time during this process. 
1. Deparaffinization/Rehydration: 
a. Incubate sections in three washes of xylene for 5 minutes each. 
b. Incubate sections in two washes of 100% ethanol for 10 minutes each. 
c. Incubate sections in two washes of 95% ethanol for 10 minutes each. 
d. Rinse sections twice in dH20 for 5 minutes each. 
2. Antigen Unmasking: 
NOTE: Consult product datasheet for specific recommendation for the unmasking solution. 
a. For Citrate: Bring slides to a boil in 10 mM sodium citrate buffer pH 6.0, then maintain at a sub-
boiling temperature for 10 minutes. Cool slides on bench top for 30 minutes. 
b. For EDTA: Bring slides to a boil in 1 mM EDTA pH. 8.0 followed by 15 minutes at a sub-boiling 
temperature. No cooling is necessary. 
3. Proceed with lmmunostaining (Section C). 
Ill. Frozen/Cryostat Sections (IF-F) 
1. For fixed frozen tissue proceed with lmmunostaining (Section C). 
., 
2. For fresh, unfixed frozen tissu,e, please fix immediately, as follows: 
a. Co~r sections with 2--4% formaldehyde in PBS. 
NOTE: Formaldehyde is toxic, use only in fume hood. 
b. Allow sections to fix for 15 minutes at room temperatuce. 
. ~ . 
c. Rinse slides three times in PBS for 5 minutes each. 
•: 
d. Proceed with lmmunostaining (Section C). 
C. lmmunostaining 
NOTE: All subsequent incubations should be carried out at room temperature unless otherwise noted in a humid light-
tight box or covered dish/plate to prevent drying and fluorochrome fading. 
1. Block specimen in Blocking Buffer for 60 minutes. 
2. While blocking, prepare primary antibody by diluting as indicated on datasheet in Antibody Dilution Buffer. 
3. Aspirate blocking solution, apply diluted primary antibody. 
4. Incubate o~might at 4°C. 
5. Rinse three times in PBS for 5 minutes each. 
NOTE: If using primary antibodies directly conjugated with Alexa Fluor® fluorochromes, then skip to step C8. 
6. Incubate specimen in fluorochrome-conjugated secondary antibody* diluted in Antibody Dilution Buffer for 1-2 
hours at room temperature in dark. 
7. Rinse in PBS as in step 5. 
8. Coverslip slides with Prolong® Gold Antifade Reagent. 
9. For best results, examine specimens immediately using appropriate excitation wavelength. For long-term 
storage, store slides flat at 4°C protected from light. 
*Recommended Secondary Antibodies: 
Anti-Rabbit 
• Anti-Rabbit lgG (H+L). F(ab'h Fragment (Alexa Fluor~ 488 Conjugate) #4412 
"' Anti-Rabbit lgG (H+L), F(ab')2 Fragment (Alexa Fluo~ 555 Conjugate) #4413 
Anti-Rabbit lgG (H+U. F(ab')2 Fragment (Alexa Fluo~ 647 Conjugate} #4414 
Anti-Mouse 
www.cellsignal.com/support/protocols/IF.html 2/: 
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X feet ™ Transfection Reagent 
Protocol-at-a-Glance 
(PT5003-2) 
This protocol is provided for transfection with Xfect Transfection Reagent (Cat. 
Nos. 631317 & 631318). Use this procedure to transfect DNA into mammalian cells 
in a 6-well format. For other formats, please see Table I on page 2 of this protocol. 
Transfections can be carried out entirely in the presence of serum. 
A. Notes 
1. Storage & Handling 
• Thaw Xfect Polymer (100 J,Jg/J,JI) at room temperature just prior to use. Once 
thawed, store Xfect Polymer at 4°C for up to 12 months. 
• Thaw Xfect Reaction Buffer at room temperature just prior to use. Vortex after 
thawing. Once thawed, store Xfect Reaction Buffer at 4°C for up to 12 months. 
• After each use make sure that the cap for the Xfect Polymer is closed tightly 
and return to the supplied foil pouch containing desiccant. 
2. Mock transfections: Use a plasmid that does not contain your gene of interest. 
You must include a source of nucleic acids to assemble with the Xfect Polymer. 
B. Transfection Protocol 
1. Prepare cells for transfection. 
Adherent cells: One day prior to the transfection, plate cells in 1 ml of com-
plete growth medium so that the cells will be 50-80% confluent at the time 
of transfection. 
Suspension cells: Just prior to preparing complexes (step 2), plate 
5 x 105-1.25 x 106 cells in 1 ml of growth medium. 
2. Thoroughly vortex Xfect Polymer. 
6 
;3. For each transfection sample, prepare two microcentrifuge tubes: 
0 t ();Y A ),o }i.b/)J{ . Tube 1 (Plasmid DNA) Tube 2 (Polymer) 
;..,.. p z 
~ 
Clontech 
United States/Canada 
800.662.2566 
Asia Pacific 
+ 1.650.919.7300 
Europe 
+33.(0)1.3904.6880 
Japan 
+81.(0) 77.543.6116 
Clontech Laboratories, Inc. 
A Takara Bio Company 
1290Terra Bella Ave. 
Mountain View, CA 94043 
Technical Support (US) 
E-mail: tech g:clontech.com 
www.clontech.com 
3,6lt.( ~~I (5 J,Jg) Plasmid DNN ..J.Ji J,JI Xfect Polymer 
1 · (always use 0.3 ~I of Xfect Polymer 1 v 1 b.};_ J,JI Xfect Reaction Buffer per 1 ~g of plasmid DNA) 
100 J.JI Total Volume ~ J.JI Xfect Reaction Buffer 
100 J,JI Total Volume. 
NOTES: 
• These quantities are per well of a 6-we/1 plate. Please see Table I on page 2 for other formats. 
• It is~ that the X feet Polymer does not remain in aqueous solution for longer than 30 
min at room temperature. 
•sygof !Jlasi'T\.l~:tl1'!A Jlliorf<s ~est for most celllil'l~s. Ho~ever, th~:~ firsttilne you use X feet, 
~r~c<.'.~. ~~-.\E!.Stjng2.5~9~5,:P_i:l: and 7.5JJ_9~l]sing_less th!)n 2;s'llg p~rwell ~na S:.well 
plate rna · tlq1a;fo~Jransfectl0nefficiency. See Ftgure 1 on page 2. 
4. Vortex each tube well to mix. 
5. Add the Polymer solution to the DNA solution and vortex well at a medium 
speed for 10 sec. . tlr*'"%. t'\.. · 
- ,/":1 ·-t~·!l: \f-t. 
6. Incubate the samples for 10 min at room temperature to allow nanoparticle 
complexes to form. 
7. Add the entire 200 J,JI of nanoparticle complex solution (Step B.5) dropwise to 
the cell culture medium from Step B.1. Rock the plate gently back and forth to 
mix. 
(032812) 
NOTE: It is IlQ1 necessary to remove serum from your cell culture medium. It is normal for the 
medium to change color slightly upon addition of the nanoparticle complex solution. 
q )./[ )ld 
{.rJ f" ( 
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Xfect™ Transfection Reagent Protocol-at-a-Glance 
8. Incubate the plate at 3JCC for 4 hr to overnight. 
NOTE: 4 hr incubation with Xfect-DNA nanoparticles is sufficient for optimal transfection. Incubation overnight is possible 
for convenience but does not generally increase transfection efficiency. If you have sensitive cells we recommend incubat-
ing for no more than 4 hr. 
9. Remove nanoparticle complexes from cells by aspiration, replace with 2 ml fresh complete growth 
medium, and return the plate to the 3JCC incubator until time of analysis. Peak expression is typically 
reached 48 hr posttransfection. 
Culture Vessel Surface Area/ 
Well 
24-well plate 2,,cm2 ,,' 
12-well plate 4cm2 
6-wellplate .. 1ocm2 ·• 
10 em dish 60 cm2 
80 
& 60 
I 
.. 40 
20 
Table I. Scaling XfectTransfections Up or Down 
Growth DNA DNA Dilution 
Medium Volume (in Xfect 
Reaction ~uffer) 
_250~1 •• 0.5-1 ~g 25~1 
500111 1-2.51Jg 50111 
,1_ml 2:~7.5pg 100(JI 
10 ml 20-40 IJg 600111 
Plasmid DNA {~g) 
Xfect Polymer 
Volume 
Alwaysll~e 
0.31JI of.Xflfct. 
. ,· Polvrnef frir •.... 
every 1 (Jg of 
~plasmid 
• Transfection 
Efficiency 
(%AcGFP1 
positive) 
+Relative 
Viability 
(%live cells) 
Polymer Dilution 
Volume (in Xfect 
Reaction Buffer) 
·. 
25J,JI . 
50111 
.. 
10.01JI 
600 IJI 
Figure 1. Transfection of Hela Cells in a 6-well plate using Xfect Increasing the amount of DNA+ Xfect Polymer significantly 
increases efficiency without affecting viability. 5 ~g of plasmid DNA works best for most cell lines. 
Notice to Purchaser 
Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, 
use in drugs, in vitro diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, 
modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of 
Clontech Laboratories, Inc. 
Your use of this product is also subject to compliance with any applicable licensing requirements described on the product's web page at 
http://www.clontech.com. It is your responsibility to review, understand and adhere to any restrictions imposed by such statements. 
Clontech, the Clontech logo, and X feet are trademarks of Clontech Laboratories, Inc. All other marks are the property of their respective 
owners. Certain trademarks may not be registered in all jurisdictions. Clontech is a Takara Bio Company. ©2012 Clontech Laboratories, Inc. 
This document has been reviewed and approved by the Clontech Quality Assurance Department. 
Clontech Laboratories, Inc. 
2 
www.clontech.com Protocol No. Pl5003-2 
Version No. 032812 
Appendix C
Shields 23
Appendix D: Daily Average Percent Confluency for each G418 Dose (12-well plate) 
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Appendix E: Daily Average Percent Confluency for each G418 Dose (6-well plate) 
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